Evaluation and management of dyslipidemia in patients with HIV infection. - Wikidata - awgldk - TriplyDB

Evaluation and management of dyslipidemia in patients with HIV infection.

Evaluation and management of dyslipidemia in patients with HIV infection.

http://www.wikidata.org/entity/Q34743413

about

Hypertriglyceridemia: its etiology, effects and treatment Achieving American Diabetes Association goals in HIV-seropositive patients with diabetes mellitus Dyslipidemia and adherence to the Mediterranean diet in Croatian HIV-infected patients during the first year of highly active antiretroviral therapy.Dyslipidaemia and dysglycaemia in HIV-infected patients on highly active anti-retroviral therapy in Kumasi Metropolis Genetic variants of APOC3 promoter and HLA-B genes in an HIV infected cohort in northern South Africa: a pilot study.Metabolic and neurologic consequences of chronic lopinavir/ritonavir administration to C57BL/6 mice HIV and general cardiovascular risk.Echocardiography and carotid intima-media thickness among asymptomatic HIV-infected adolescents in Thailand.A Prospective, Multicentre, Open-Label Single-Arm Exploratory Study to Evaluate Efficacy and Safety of Saroglitazar on Hypertriglyceridemia in HIV Associated Lipodystrophy.The next generation of HIV/AIDS drugs: novel and developmental antiHIV drugs and targets.HIV protease inhibitors block the zinc metalloproteinase ZMPSTE24 and lead to an accumulation of prelamin A in cells.Atazanavir--a once-daily HIV protease inhibitor that does not cause dyslipidemia in newly treated patients: results from two randomized clinical trials.Strategies for management and treatment of dyslipidemia in HIV/AIDS.Can Metabolic Factors be used Prognostically for Short-Term Mortality in HIV-Infected Patients?Minocycline- and tetracycline-induced hypertriglyceridemia in an HIV-seropositive patient receiving combination antiretroviral therapy.A potent HIV protease inhibitor, darunavir, does not inhibit ZMPSTE24 or lead to an accumulation of farnesyl-prelamin A in cells.Drug therapies for HIV-related metabolic disorders.The impact of comorbidities on costs, utilities and health-related quality of life among HIV patients in a clinical setting in Bogotá.Hypertriglyceridemia in a pediatric referral practice: experience with 300 patients.Effectiveness and tolerability of oral administration of low-dose salmon oil to HIV patients with HAART-associated dyslipidemia.Balancing disfigurement and fear of disease progression: Patient perceptions of HIV body fat redistribution.Prevalence of risk factors for cardiovascular disease in HIV-infected patients over time: the Swiss HIV Cohort Study

P2860

Q24672914-2954B179-64B6-429B-86DF-72628FF0F749 Q28222271-A72F0C13-C0D2-471D-9A54-591B7B0A26E9 Q33747646-B372592F-E8A6-4619-A2F8-F182FDE84920 Q33751516-BFEB8B86-EF0F-4FA1-ACB4-A4FF3C13305B Q34072196-F6CD4DD3-D811-4507-8ECF-F1789D90C9FC Q34349192-07860458-20AA-4843-A6BC-2E3C8CC37065 Q35118909-01A862B1-A98A-4DB6-B591-7B727E1262AC Q35582669-00A3285C-762C-4486-B540-D34497582741 Q35899038-CA72D60B-F5CB-4D32-89CE-20EEB3D7614B Q35917148-1CC92DF8-CF30-46F1-8ED7-A598656B0F35 Q35941280-DE9BF8AE-E0BD-4B72-AB11-CEFFDA218DE5 Q35968731-D943265A-40F0-4568-ACA0-B8D1521273DF Q36336563-9D932B07-D5A1-4A44-9A2F-B43BB647ED4B Q36612849-F249C205-71BD-4383-9EFB-36BFD3C61E75 Q36714593-C524B367-134B-4F0B-9762-8AD86A45A214 Q36741508-BB5C5E61-E617-431C-B53F-397D5E0283C1 Q38837421-31025E84-BCC9-4035-96D5-715521DAA733 Q40509615-2BA4B8AE-9BC9-4254-838D-FA01566E18AC Q45134279-DB82E18E-0F47-4533-8466-48194A718D75 Q46879488-A5511315-D7D4-4E2A-9DDF-F5317D454A23 Q50925529-6A1D87CD-81A7-45A2-A8AA-B8C8BA5D32B2 Q56530639-6DE91F8C-7FED-40B6-B5E4-173EF2C39C94

P2860

Evaluation and management of dyslipidemia in patients with HIV infection.

http://www.wikidata.org/entity/Q34743413

description

2002 nî lūn-bûn

@nan

2002 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2002 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu

name

Evaluation and management of dyslipidemia in patients with HIV infection.

@ast

Evaluation and management of dyslipidemia in patients with HIV infection.

@en

Evaluation and management of dyslipidemia in patients with HIV infection.

@nl

type

label

Evaluation and management of dyslipidemia in patients with HIV infection.

@ast

Evaluation and management of dyslipidemia in patients with HIV infection.

@en

Evaluation and management of dyslipidemia in patients with HIV infection.

@nl

prefLabel

Evaluation and management of dyslipidemia in patients with HIV infection.

@ast

Evaluation and management of dyslipidemia in patients with HIV infection.

@en

Evaluation and management of dyslipidemia in patients with HIV infection.

@nl

P1433

Q34743413-B50AFA19-FA8D-48EB-8325-C3E5A9DEB413

P1476

Q34743413-A884FCE3-EB36-4465-AEF8-C4C14A96A537

P2093

Q34743413-DE842A46-D6D3-42E1-9864-FC78BB7AECD4

P2860

Q34743413-009ED471-8E37-42A7-AB6E-FDAA16AF197B

Q34743413-055B9434-5CE6-49C7-96D3-2C42ED772DCC

Q34743413-05896F5A-FB82-41F8-B5F1-9980E167918F

Q34743413-0595E61A-4012-499E-A9CA-49801B4784E3

Q34743413-05C42D0D-926E-4E60-BFB3-52C1DC68C05A

Q34743413-0841110A-4905-416A-AC40-B5ED478A1AE4

Q34743413-0A3B9087-D69D-4F74-9185-A036BEA7C20C

Q34743413-0FD1009F-B2F7-4DC7-841F-E2685DB89584

Q34743413-1143B1C9-88AC-44C0-93FC-78AFCAE1FBB2

Q34743413-11A96149-5101-451F-A45E-8560778F19F3

P2888

Q34743413-504BF554-7D2B-4DC6-85C8-00A0E7D1F0AD

P304

Q34743413-B7F37951-857E-4F3B-A39F-9B98DF922C5C

P31

Q34743413-C5D362EB-544B-4BE2-85D5-15A71D0B6676

P356

Q34743413-7FD79355-4093-4A01-8A37-02977C3CF2CD

P433

Q34743413-232385FD-76B3-4820-8EF9-3A8E4E124F0D

P478

Q34743413-1B5E89E2-831C-484C-9F18-B692D216FEB1

P577

Q34743413-F8417531-FA4D-4DEC-8152-55982EA7001A

P5875

Q34743413-BD2C710D-BD2A-47A2-A1A0-BA19C6FC3C86

P6179

Q34743413-4D49141F-1413-4FFB-9134-4E7548D88A53

P698

Q34743413-5EB27529-DC1A-4704-B38E-7B7A8AC5F650

P921

Q34743413-503B128C-2F12-4EA0-A4A6-0F2F15623836

P932

Q34743413-315D9DF7-AFF8-4004-8772-D948B94A99F4

P356

J.1525-1497.2002.20201.X

P1433

Journal of General Internal Medicine

P1476

Evaluation and management of dyslipidemia in patients with HIV infection.

@en

P2093

Michael L Green

http://www.w3.org/2001/XMLSchema#string

P2860

Prediction of Coronary Heart Disease Using Risk Factor Categories

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

Niacin-induced hepatitis: a potential side effect with low-dose time-release niacin

Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

Lipodystrophy-associated morphological, cholesterol and triglyceride abnormalities in a population-based HIV/AIDS treatment database.

Alterations of apolipoprotein B metabolism in HIV-infected patients with antiretroviral combination therapy.

Drug treatment of lipid disorders.

Hyperlipidemia associated with protease inhibitor therapy.

Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy.

P2888

j.1525-1497.2002.20201.x

P304

797-810

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1046/J.1525-1497.2002.20201.X

http://www.w3.org/2001/XMLSchema#string

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

17

http://www.w3.org/2001/XMLSchema#string

P577

2002-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

11071037

http://www.w3.org/2001/XMLSchema#string

P6179

1046419693

http://www.w3.org/2001/XMLSchema#string

P698

12390557

http://www.w3.org/2001/XMLSchema#string

P921

P932

1495116

http://www.w3.org/2001/XMLSchema#string